Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)

Phase 2

Completed

• Conditions: Viral Conjunctivitis
• Interventions: Drug: APD-209 Eye drops; Drug: APD-209 Placebo Eye drops

• Registration Number: NCT01977443
• Lead Sponsor: Adenovir Pharma AB

Brief Summary

A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase adenovirus-induced EKC. The aims of the study are to investigate the therapeutic efficacy of APD-209 Eye drops as measured by adenoviral load, time to viral eradication, clinical resolution of EKC (objective and subjective assessments), presence of opacities, visual acuity and frequency of second eye infections, and to assess the safety and tolerability of APD-209 Eye drops in EKC infected eyes.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-10-31
• Study Start: 2013-11
• Study First Submitted QC: 2013-11-05
• Study First Posted: 2013-11-06
• Primary Completion: 2016-09
• Study Completion: 2016-09
• Status Verified: 2016-11
• Last Update Submitted: 2016-11-01
• Last Update Posted: 2016-11-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

The patients have to meet all of the following criteria to be eligible to enter the study:

• Willing and able to provide informed consent.
• Men or women aged 18 years or above with onset of adenoviral EKC symptoms in at least one eye, as clinically diagnosed and with symptoms appearing within less 7 days at the time of giving informed consent.
• Using adequate contraceptive measures

Exclusion Criteria

• Known or suspected allergy to any ingredient of the IMP or placebo.
• Symptoms correlating with EKC since more than 7 days.
• Diagnosis of other significant disease(s) than EKC in the eye.
• Diagnosis of bacterial or fungal ocular infections.
• Use of antibiotics or corticosteroids by any route (except intravitreal corticosteroids) within 14 days prior to inclusion. Ocular antibiotics may, however, be used until 2 hours prior to first dose of IMP, but are thereafter prohibited during the study.
• Use of immunosuppressive medications (including intravitreal corticosteroids) within 6 months prior to inclusion.
• Use of antiviral medications within 7 days prior to inclusion.
• Usage of any medication or herbal medicinal product with documented adverse reactions affecting the eyes.
• Usage of any medication or herbal medicinal product for ocular administration at inclusion.
• Female patients: currently pregnant or breast-feeding or intending to become pregnant during the study period.
• Known or suspected drug abuse.
• Usage of contact lenses during the study.
• Participation in any other interventional clinical study within 30 days prior to inclusion

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
APD-209 Eye drops	APD-209 Eye drops	APD-209 Eye drops
APD-209 Placebo Eye drops	APD-209 Placebo Eye drops	APD-209 Placebo Eye drops

Primary Outcome Measures

Name	Time	Method
The primary objective is to assess the adenoviral load in epidemic keratokonjunctivitis (EKC) infected eyes following topical treatment with APD-209 Eye drops compared to placebo.	14 days	Viral load in tear liquid from EKC infected eyes, as measured by the area under the curve (AUC) at 3-14 days from start of treatment.

Secondary Outcome Measures

Name	Time	Method
Assess the time to viral eradication in EKC infected eyes following treatment with APD-209 Eye drops compared to placebo.	14 days	The time point of viral eradication in tear liquid from EKC infected eyes, defined as the time Point when viral load=0 or below the lower limit of quantification (LLOQ).
Evaluate the effect of APD-209 Eye drops on clinical resolution of EKC, as measured by objective and subjective assessment of scaled clinical symptoms, compared to placebo.	14 days	Resolution of acute ocular symptoms at each time of assessment, as measured by objective (Investigator-based) assessment of conjunctival discharge and redness.
Evaluate the presence of opacities (quantitatively and qualitatively) following treatment with APD-209 Eye drops compared to placebo.	14 days	Presence and location of opacities at each time of assessment, as measured by slit lamp examination.
Assess the visual acuity following treatment with APD-209 Eye drops compared to placebo.	28 days	Visual acuity at each time of assessment by use of the logarithm of the Minimum Angle of Resolution (LogMAR) chart.
Assess the frequency of second eye infections.	14 days	Occurrence of second eye infection.
Assess the safety and tolerability of APD-209 Eye drops.	14 days	Safety variables: adverse events (AEs) (nature and incidence), Physical examination, vital signs, laboratory safety assessments (haematology, clinical chemistry and urinalysis)

Trial Locations

Locations (10)

Katowice University Hospital; 🇵🇱 Katowice, Poland

St Eriks Eye Hospital; 🇸🇪 Stockholm, Sweden

P. Oleksy Centrum Medyczne Uno-Med; 🇵🇱 Tarnow, Poland

Augenklinik Universitätzmedizin Charité; 🇩🇪 Berlin, Germany

Universitäts-Augenklinik Freiburg; 🇩🇪 Freiburg, Germany

Universitäts-klinikum Schleswig-Holstein; 🇩🇪 Lübeck, Germany

Augenklinik, Universitätsklinikum Tübingen; 🇩🇪 Tübingen, Germany

Universitäts-Augenklinik; 🇩🇪 Würzburg, Germany

Universitätsklinikum Düsseldorf; 🇩🇪 Düsseldorf, Germany

Augenklinik Köln, Merheim; 🇩🇪 Köln, Germany